Noah AI Industry News

Delivers real-time biopharma news and signals — powered by AI, curated for professionals.

Latest Developments in Diabetes and Obesity Therapies Take Center Stage at EASD 2025

The European Association for the Study of Diabetes (EASD) annual meeting, set to take place from September 15 to 19 in Vienna, Austria, promises to shed light on pivotal advancements in diabetes and obesity treatments. This year's conference comes at a crucial juncture, following several high-profile readouts that have reshaped the cardiometabolic landscape.

NoahAI News9/15/2025

Rush of Targeted Myasthenia Gravis Therapies Transforms Treatment Landscape

The pharmaceutical industry is witnessing a surge in the development and approval of targeted therapies for myasthenia gravis (MG), a rare autoimmune disorder affecting neuromuscular junctions. This rapid expansion of treatment options is reshaping the market and offering new hope for patients who have long struggled with limited therapeutic choices.

NoahAI News9/15/2025

FDA Action Alert: Key Decisions Loom for Merck, Sanofi, Biogen and More

The U.S. Food and Drug Administration (FDA) is set to make a series of critical decisions in the latter half of September, potentially shaping the future of several pharmaceutical companies and their innovative therapies. From subcutaneous formulations of blockbuster drugs to novel treatments for rare genetic disorders, the agency's rulings could significantly impact patient care across multiple therapeutic areas.

NoahAI News9/15/2025

AI-Powered Startup Revolutionizes Provider Credentialing, Raising $6M in Seed Funding

Assured, a new player in the healthcare technology sector, has secured $6 million in seed funding to accelerate the traditionally slow process of provider credentialing. The startup's artificial intelligence-driven platform promises to reduce credentialing time from months to days, potentially saving healthcare organizations thousands of dollars per provider monthly.

NoahAI News9/15/2025

Pharmaceutical Industry Faces Widespread Layoffs Amid Strategic Shifts and Financial Pressures

The pharmaceutical and biotech sectors are experiencing a significant wave of workforce reductions as companies realign their strategies, prioritize pipelines, and grapple with financial constraints. This comprehensive overview examines the latest developments in layoffs, restructuring efforts, and their implications for the industry.

NoahAI News9/13/2025

AbbVie Secures Extended Exclusivity for Rinvoq, Bolstering Immunology Portfolio

AbbVie has successfully negotiated a settlement with generic manufacturers, extending the market exclusivity of its JAK inhibitor Rinvoq in the United States until 2037. This development comes as a significant boost to the company's efforts to offset revenue losses from its blockbuster drug Humira, which has faced increased competition from biosimilars.

NoahAI News9/13/2025

Eli Lilly Pauses UK Biotech Incubator Plans Amid Industry Concerns

Pharmaceutical giant Eli Lilly has put its plans for a UK-based Gateway Labs biotech incubator on hold, citing uncertainties in the British life sciences sector. This decision comes as part of a broader reassessment of the company's £279 million investment commitment to the UK, agreed upon with the government last year.

NoahAI News9/13/2025

Philips and Masimo Extend Patient Monitoring Partnership with Focus on AI and Wearables

Philips and Masimo have announced a renewal of their long-standing collaboration in patient monitoring, expanding their focus to include the development of next-generation vital sign readers and artificial intelligence-powered solutions. The multi-year strategic agreement aims to integrate advanced monitoring technologies and develop new tools to enhance patient care.

NoahAI News9/13/2025

Galimedix's Oral Alzheimer's Drug Advances to Phase 2 After Successful Safety Trial

Maryland-based biotech company Galimedix Therapeutics has announced the successful completion of a phase 1 trial for its oral Alzheimer's disease candidate, GAL-101. The small molecule demonstrated a favorable safety profile and effectively crossed the blood-brain barrier, paving the way for phase 2 studies and potential fundraising efforts.

NoahAI News9/13/2025

GLP-1 Drugs Show Promise Beyond Weight Loss: Potential Applications in Cancer Treatment

GLP-1 receptor agonists, known for their powerful weight loss benefits, are emerging as potential game-changers in the field of oncology. Deborah Phippard, chief scientific officer at Precision for Medicine, describes these drugs as "some of the most complicated" she has seen in her career, citing their wide-ranging effects on multiple biological pathways.

NoahAI News9/13/2025

CVS Health Announces Leadership Changes in Care Delivery Businesses

CVS Health, a major player in the healthcare industry, has made significant changes to its leadership structure, particularly in its care delivery businesses. These moves come as the company continues to navigate the complex healthcare landscape and integrate its recent acquisitions.

NoahAI News9/13/2025

AI Drives Investment and Acquisitions in Medtech Sector

Artificial intelligence (AI) is emerging as a dominant force in the medical technology landscape, attracting significant investment and driving strategic acquisitions in 2025. Despite a overall decrease in funding rounds during the first half of the year, AI-focused startups have become increasingly attractive to investors, signaling a shift in industry priorities.

NoahAI News9/13/2025

«1 2 3 4...67 »